Differential expression of the regularly spliced wild-type p53 and its COOH-terminal alternatively spliced form during epidermal differentiation

Cell Growth and Differentiation

Volumn 8, Issue 8, 1997, Pages 851-860

  Rehberger, Petra A ^a   Richter, K Hartmut ^a   Schwartz, Dov ^b   Goldfinger, Naomi ^b   Oskato, Ronit ^b   Almog, Nava ^b   Marks, Friedrich ^a   Rotter, Varda ^b  

^a Deutsches Krebsforschungzentrum ^*  (Germany)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL SELECTION; FROZEN SECTION; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; KERATINOCYTE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; SKIN BIOPSY; TUMOR SUPPRESSOR GENE;

ALTERNATIVE SPLICING; ANIMALS; ANIMALS, NEWBORN; CELL CYCLE; CELL DIFFERENTIATION; CELL NUCLEUS; CELLS, CULTURED; CYTOPLASM; EPIDERMIS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; KERATINOCYTES; MICE; RNA SPLICING; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030796188     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Mercer, W. E., Shields, M. T., Amin, M., Sauve, G. J., Appella, E., Romand, J. W., and Ullrich, S. J. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild type p53. Proc. Natl. Acad. Sci. USA, 87: 6166-6170, 1990.
2. Michalovitz, D., Halevy, O., and Oren, M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell, 62: 671-680, 1990.
3. Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., Vogelstein, B., and Friend, S. H. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol., 10: 5772-5781, 1990.
4. Shaulsky, G., Goldfinger, N., Peled, A., and Rotter, V. Involvement of wild type p53 in pre-B cell differentiation in vitro. Proc. Natl. Acad. Sci. USA, 88: 8982-8986, 1991.
5. Ryan, J. J., Danish, R., Gottlieb, C. A., and Clarke, M. F. Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells. Mol. Cell. Biol., 13: 711-719, 1993.
6. Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., and Wahl, G. M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70: 937-948, 1992.
7. 1 arrest. Cell, 76: 1013-1023, 1994.
8. Yonish-Rouach, E., Resnitzky, K., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature (Lond.), 352: 345-347, 1991.
9. Yonish-Rouach, E., Grunwald, D., Wilder, S., Kimchi, A., May, E., Lawrence, J. J., May, P., and Oren, M. p53-mediated cell death: relationship to cell cycle control. Mol. Cell. Biol., 13: 1415-1423, 1993.
10. Oren, M. Relationship of p53 to the control of apoptotic cell death. Semin. Cancer Biol., 5: 221-227, 1994.
11. Aloni-Grinstein, R., Schwartz, D., and Rotter, V. Accumulation of wild type p53 protein upon y-irradiation induces a G2-dependent immunoglobulin κ light chain gene expression. EMBO J., 14: 1392-1401, 1995.
12. Ronen, D., Schwartz, D., Teitz, Y., Goldfinger, N., and Rotter, V. Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild type p53 protein whereas their differentiation is mediated by lower p53 levels. Cell Growth & Differ., 7: 21-30, 1996.
13. Rotter, V., Aloni-Grinstein, R., Schwartz, D., Elkind, N. B., Simons, A., Wolkowicz, R., Lavigne, M., Besserman, P., Kapon, A., and Goldfinger, N. Does wild type p53 play a role in normal cell differentiation? Semin. Cancer Biol., 5: 229-236, 1994.
14. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
15. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
16. Lu, X., and Lane, D. P. Differential induction of transcriptionally active p53 following UV or ionizing irradiation: defects in chromosome instability syndromes? Cell, 75: 765-778, 1993.
17. Nelson, W. G., and Kastan, M. B. DNA strand breaks: the DNA template alteration that triggers p53 dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815-1823, 1994.
18. Cross, S. M., Sanchez, C. A., Morgan, C. A., Schimke, M. K., Ramel, S., Idzerda, R. L., Raskind, W. H., and Reid, B. J. A p53-dependent mouse spindle checkpoint. Science (Washington DC), 267: 1353-1356, 1995.
19. Wells, W. A. E. The spindle-assembly checkpoint: aiming for a perfect mitosis, every time. Trends Cell Biol., 6: 228-234, 1996.
20. Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S., and Vande Woude, G. F. Abnormal centrosome amplification in the absence of p53. Science (Washington DC), 271: 1744-1747, 1996.
21. Peled, A., Schwartz, D., Elkind, N. B., Wolkowicz, R., Li, R., and Rotter, V. The role of p53 in the induction of polyploidity of myelomonocytic leukemic M1/2 cells. Oncogene, 13: 1677-1685, 1996.
22. Milner, J., and Watson, A. J. Addition of fresh medium induces cell-cycle and conformation changes in p53, a tumor suppressor protein. Oncogene, 5: 1683-1690, 1990.
23. Hainaut, P., and Milner, J. A structural role for metal ions in the "wild-type" conformation of the tumor suppressor protein p53. Cancer Res., 53: 1739-1742, 1993.
24. Fields, S., and Jang, S. K. Presence of potent transcription activating sequences in the p53 protein. Science (Washington DC), 249: 1046-1049, 1990.
25. Raycroft, L., Wu, H., and Lozano, G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science (Washington DC), 249: 1049-1051, 1990.
26. O'Rourke, R. W., Miller, C. W., Kato, G. J., Simon, K. J., Chen, D-L., Dang, C. V., and Koeffler, H. P. A potential transcriptional activation element in the p53 protein. Oncogene, 5: 1829-1832, 1990.
27. Bargonetti, J., Manfredi, J. J., Chen, X., Marshak, D. R., and Prives, C. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev., 7: 2565-2574, 1993.
28. Pavletich, N. P., Chambers, K. A., and Pabo, C. O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev., 7: 2556-2564, 1993.
29. Wang, Y., Reed, M., Wang, P., Stenger, J. E., Mayr, G., Anderson, M. E., Schwedes, J. F., and Tegtmeyer, P. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev., 7: 2575-2586, 1993.
30. Cho, Y., Gorina, S., Jeffrey, P. D., and Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (Washington DC), 265: 346-355, 1994.
31. Hupp, T. R., Meek, D. W., Midgley, C. A., and Lane, D. P. Regulation of the specific DNA binding function of p53. Cell, 71: 875-886, 1992.
32. Milner, J., Medcalf, E. A., and Cook, A. C. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol. Cell. Biol., 11: 12-19, 1991.
33. Slingerland, J. M., Jenkins, J. R., and Benchimol, S. The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. EMBO J., 12: 1029-1037, 1993.
34. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
35. Tarunina, M., and Jenkins, J. R. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity. Oncogene, 8: 3165-3173, 1993.
36. Clore, G. M., Omichinski, J. G., Sakaguchi, K., Zambrano, N., Sakamoto, H., Appella, E., and Gronenborn, A. M. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science (Washington DC), 265: 386-394, 1994.
37. Hupp, T. R., Meek, D. W., Midgley, C. A., and Lane, D. P. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res., 21: 3167-3174, 1993.
38. Wu, Y., Liu, Y., Lee, L., Miner, Z., and Kulesz-Martin, M. Wild-type alternatively spliced p53: binding to DNA and interaction with the major p53 protein in vitro and in cells. EMBO J., 13: 4823-4830, 1994.
39. Wolkowicz, R., Peled, A., Elkind, N. B., and Rotter, V. The augmented DNA binding activity of an alternative spliced C′-terminal p53 is blocked by regular spliced p53 protein. Proc. Natl. Acad. Sci. USA, 92: 6842-6846, 1995.
40. Bayle, J. H., Elenbaas, B., and Levine, A. J. The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc. Natl. Acad. Sci. USA, 92: 5729-5733, 1995.
41. Sturzbecher, H-W., Donzelmann, B., Henning, W., Knippschild, U., and Buchhop, S. p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J., 15: 1992-2002, 1996.
42. Dutta, A., Ruppert, J. M., Aster, J. C., and Wincherester, E. Inhibition of DNA replication factor RPA by p53. Nature (Lond.), 365: 79-82, 1993.
43. Wang, X. W., Forrester, K., Yeh, H., Feitelson, M. A., Gu, J., and Harris, C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA, 91: 2230-2234, 1994.
44. Wang, X. W., Yeh, H., Schaeffer, L., Roy, R., Moncolli, V., Egly, J-M., Wang, Z., Friedberg, E. C., Evans, M. K., Taffe, B. G., Bohr, V. A., Weeda, G., Hoeijmakers, J. H. J., Forrester, K., and Harris, C. C. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat. Genet., 10: 188-195, 1995.
45. Jayaraman, L., and Prives, C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell, 81: 1021-1029, 1995.
46. Bakalkin, G., Yakovleva, T., Selivanova, G., Magnusson, K. P., Szekely, L., Kiseleva, E., Klein, G., Terenius, L., and Wiman, K. G. p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc. Natl. Acad. Sci. USA, 91: 413-417, 1994.
47. Bakalkin, G., Selivanova, G., Yakovleva, T., Kiseleva, E., Kashuba, E., Magnusson, K. P., Szekeley, L., Klein, G., Terenius, L., and Wiman, K. G. p53 binds single-strand DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucleic Acids Res., 23: 362-369, 1995.
48. Lee, S., Elenbaas, B., Levine, A., and Griffith, J. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell, 81: 1013-1020, 1995.
49. Wu, L., Bayle, H., Elenbaas, B., Pavletich, N. P., and Levine, A. J. Alternatively spliced forms in the carboxyl-terminal domain of the p53 protein regulate its ability to promoter annealing of complementary single strands of nucleic acids. Mol. Cell. Biol., 15: 497-504, 1995.
50. Brain, R., and Jenkins, J. R. Human p53 directs DNA strand reassociation and is photolabeled by 8-azido ATP. Oncogene, 9: 1775-1780, 1994.
51. Gottlieb, E., Lindner, S., and Oren, M. Relationship of sequence-specific transactivation and p53-regulated apoptosis in interleukin 3-dependent hematopoietic cells. Cell Growth & Differ., 7: 301-310, 1996.
52. Miyashita, T., Harigai, M., Hanada, M., and Reed, J. C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res., 54: 3131-3135, 1994.
53. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., and Liebermann, D. A. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994.
54. Wyllie, A. H. The genetic regulation of apoptosis. Curr. Opin. Genet. Dev., 5: 97-104, 1995.
55. Miyashita, T., and Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80: 293-299, 1995.
56. Almog, N., Peled, A., Li, R., Schwartz, D., Wolkowicz, R., Goldfinger, N., Huiping, P., and Rotter, V. The murine C-terminal alternatively spliced p53 form induced an attenuated apoptosis in myeloid cells. Mol. Cell. Biol., 17: 713-722, 1997.
57. Haupt, Y., Rowan, S., Shaulian, E., Vousden, K. H., and Oren, M. Induction of apoptosis in HeLa cells by frans-activation-deficient p53. Genes Dev., 9: 2170-2183, 1995.
58. Wolf, D., Harris, N., Goldfinger, N., and Rotter, V. Isolation of full-length mouse cDNA clone coding for an immunologically distinct p53 molecule. Mol. Cell. Biol., 5, 127-132, 1985.
59. Arai, N., Nomura, D., Yokota, K., Wolf, D., Brill, E., Shohat, O., and Rotter, V. Immunologically distinct p53 molecules generated by alternative splicing. Mol. Cell. Biol., 6: 3232-3239, 1986.
60. Han, K., and Kulesz-Martin, M. F. Alternatively spliced p53 RNA in transformed and normal cells of different tissue types. Nucleic Acids Res., 20: 1979-1981, 1992.
61. Kulesz-Martin, M. F., Lisafeld, B., Huang, H., Kisiel, N. D., and Lee, L. Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells. Mol. Cell. Biol., 14: 1698-1708, 1994.
62. Fuchs, E. Epidermal differentiation: the bare essentials. J. Cell Biol., 111: 2807-2814, 1990.
63. Woodworth, C. D., Wang, H., Simpson, S., Alvarez-Salas, L. M., and Notario, V. Overexpression of wild-type p53 alters growth and differentiation of normal human keratinocytes but not human papillomavirus-expressing cell lines. Cell Growth & Differ., 4: 367-376, 1993.
64. 1. Cell Growth & Differ., 4: 993-1004, 1993.
65. Healy, E., Reynolds, N. J., Smith, M. D., Campbell, C., Farr, P. M., and Rees, J. L. Dissociation of erythema and p53 protein expression in human skin following UVB irradiation, and induction of p53 protein and mRNA following application of skin irritants. J. Invest. Dermatol., 103: 493-499, 1994.
66. Sebag, M., Gulliver, W., and Kremer, R. Effect of 1,25-dihydroxyvitamin D3 and calcium on growth and differentiation and on c-fos and p53 gene expression in normal human keratinocytes. J. Invest. Dermatol., 103: 323-329, 1994.
67. Spandau, D. F. Distinct conformations of p53 are observed in different stages of keratinocyte differentiation. Oncogene, 9: 1861-1868, 1994.
68. Almon, E., Goldfinger, N., Kapon, A., Schwartz, D., Levine, A. J., and Rotter, V. Testicular tissue-specific expression of the p53 suppressor gene. Dev. Biol., 156: 107-116, 1993.
69. Kastan, M. B., Radin, A. I., Kuerbitz, S. J., Onyekwere, O., Wolkow, C. A., Civin, C. I., Stone, K. D., Woo, T., Ravindranath, Y., and Craig, R. W. Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res., 51: 4279-4286, 1991.
70. Johnson, P., Chung, S., and Benchimol, S. Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobulin production and is sensitive to erythropoietin. Mol. Cell. Biol., 13: 1456-1463, 1993.
71. Feinstein, E., Gale, P. B., Reed, J., and Cannai, E. Expression of the normal p53 gene induces differentiation of K562 cells. Oncogene, 7: 1853-1857, 1992.
72. Soddu, S., Blandino, G., Citro, G., Scardigli, R., Piaggio, G., Ferber, A., Calabretta, B., and Sacchi, A. Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood, 83: 2230-2237, 1994.
73. Soddu, S., Blandino, G., Scardigli, R., Coen, S., Marchetti, A., Rizzo, M. G., Bossi, G., Cimino, L., Crescenzi, M., and Sacchi, A. Interference with p53 protein inhibits hematopoietic and muscle differentiation. J. Cell Biol., 134: 1-12, 1996.
74. Shaulsky, G., Goldfinger, N., and Rotter, V. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res., 51: 5232-5237, 1991.
75. Aloni-Grinstein, R., Zan-Bar, I., Alboum, I., Goldfinger, N., and Rotter, V. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage. Oncogene, 8: 3297-3305, 1993.
76. van Gent, D. C., Ramsden, D. A., and Gellert, M. The RAG1 and RAG2 proteins establish the 12/23 rule in V(D)J recombination. Cell, 85: 107-113, 1996.
77. Bogue, M. A., Zhu, C., Aguilar-Cordova, E., Donehower, L. A., and Roth, D. B. p53 is required for both radiation-induced differentiation and rescue of V(D)J rearrangement in seid mouse thymocytes. Genes Dev., 10: 553-565, 1996.
78. Schwartz, D., Goldfinger, N., and Rotter, V. Expression of p53 protein in spermatogenesis is confined to the tetraploid pachytene primary spermatocytes. Oncogene, 8: 1487-1494, 1993.
79. Rotter, V., Schwartz, D., Almon, E., Goldfinger, N., Kapon, A., Meshorer, A., Donehower, L. A., and Levine, A. J. Mice with reduced levels of p53 exhibit the testicular giant cell degenerative syndrome. Proc. Natl. Acad. Sci. USA, 90: 9075-9079, 1993.
80. Brash, D. E., Rudolph, J. A., Simon, J. A., Lin, A., McKenna, G. J., Baden, H. P., Halperin, A. J., and Ponten, J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA, 88: 10124-10128, 1991.
81. Ziegler, A., Jonason, A. S., Leffell, D. J., Simon, J. A., Sharma, H. W., Kimmelman, Remington, L., Jacks, T., and Brash, D. E. Sunburn and p53 in the onset of skin cancer. Nature (Lond.), 372: 773-776, 1994.
82. Kamb, A. Sun protection factor p53. Nature (Lond.), 372: 730-731, 1994.
83. Cui, W., Kemp, C. J., Duffie, E., Balmain, A., and Akhurst, R. J. Lack of transforming growth factor-β1 expression in benign skin tumors of p53 null mice is prognostic for a high risk of malignant conversion. Cancer Res., 54: 5831-5836, 1994.
84. Ginsberg, D., Michael-Michaelovitz, D., and Oren, M. Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. Mol. Cell. Biol., 11: 582-585, 1991.
85. Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A., and Rotter, V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell. Biol., 10: 6565-6577, 1990.
86. Yuspa, S. H., and Harris, C. C. Altered differentiation of mouse epidermal cells treated with retinyl acetate in vitro. Exp. Cell Res., 86: 95-105, 1974.
87. Furstenberger, G., Gross, M., Schweizer, J., Vogt, I., and Marks, F. Isolation, characterization and in vitro cultivation of subfractions of neonatal mouse keratinocytes: effects of phorbol esters. Carcinogenesis (Lond.), 7: 1745-1753, 1986.
88. Gannon, J. V., Greaves, R., Iggo, R., and Lane, D. P. Activating mutations in p53 produce a common conformational effect: a monoclonal antibody specific for the mutant form. EMBO J., 9: 1595-1602, 1990.
89. Yewdell, J. W., Gannon, J. V., and Lane, D. P. Monoclonal antibody analysis of p53 expression in normal and transformed cells. J. Virol., 59: 444-452, 1986.
90. Harlow, E., Crawford, L. V., Pim, D. C., and Williamson, N. M. Monoclonal antibodies specific for simian virus 40 tumor antigen. J. Virol., 39: 861-869, 1981.